MESC Stock Overview
Lophos Holdings Inc., through its subsidiary, Lophos Pharmaceuticals Corp.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lophos Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.05 |
| 52 Week High | CA$0.30 |
| 52 Week Low | CA$0.03 |
| Beta | 0 |
| 1 Month Change | -16.67% |
| 3 Month Change | -37.50% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.74% |
Recent News & Updates
Shareholder Returns
| MESC | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -33.3% | -0.1% | 0.8% |
| 1Y | n/a | 47.9% | 4.8% |
Return vs Industry: Insufficient data to determine how MESC performed against the Canadian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MESC performed against the Canadian Market.
Price Volatility
| MESC volatility | |
|---|---|
| MESC Average Weekly Movement | 61.9% |
| Pharmaceuticals Industry Average Movement | 13.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in CA Market | 18.0% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MESC's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MESC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jacqueline Lupo | lophos.com |
Lophos Holdings Inc., through its subsidiary, Lophos Pharmaceuticals Corp. focuses on the cultivation and research of peyote cactus. It researches and sells compounds within the peyote cactus, including mescaline for drug development. The company is headquartered in Vancouver, Canada.
Lophos Holdings Inc. Fundamentals Summary
| MESC fundamental statistics | |
|---|---|
| Market cap | CA$4.29m |
| Earnings (TTM) | -CA$1.22m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs MESC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MESC income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$1.22m |
| Earnings | -CA$1.22m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.014 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 111.6% |
How did MESC perform over the long term?
See historical performance and comparison